These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7911657)

  • 41. Proceedings of the meeting New Insights and Therapeutic Strategies in Cardiovascular Disease: Focus on Endothelial Targets. Venice, Italy, April 28-29, 2000.
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S1-87. PubMed ID: 12125590
    [No Abstract]   [Full Text] [Related]  

  • 42. Issues regarding public screening for cholesterol levels in Australia.
    James R; Tyler C; Van Beurden E
    Aust Health Rev; 1989; 12(1):56-64. PubMed ID: 10294853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychosomatic medicine: new facts and old controversies. Part I. Proceedings of the 9th world congress of the College of Psychosomatic Medicine. Sydney, Australia, August 30-September 4, 1987.
    Psychother Psychosom; 1987; 47(3-4):127-227. PubMed ID: 3505694
    [No Abstract]   [Full Text] [Related]  

  • 44. Mild hypertension as a cardiovascular risk factor.
    Kannel WB
    Compr Ther; 1981 Oct; 7(10):7-14. PubMed ID: 7297051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Were you aware of these five typical issues on your heart?
    Bruce MM
    Int J Occup Environ Med; 2011 Jul; 2(3):184-5. PubMed ID: 23022836
    [No Abstract]   [Full Text] [Related]  

  • 46. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study.
    Tan JS; Mitchell P; Smith W; Wang JJ
    Ophthalmology; 2007 Jun; 114(6):1143-50. PubMed ID: 17275090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reducing CVD risk - integration of clinical and laboratory criteria.
    Tognarini DP; Sullivan DR; Thomas DW; Sikaris K
    Aust Fam Physician; 2008 Jun; 37(6):422-7. PubMed ID: 18523695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors for cardiovascular illness in panic disorder patients.
    Yeragani VK; Pohl R; Balon R; Ramesh C; Glitz D; Sherwood P
    Neuropsychobiology; 1990-1991; 23(3):134-9. PubMed ID: 2098670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular remodeling and its correction: a comprehensive strategy. Proceedings of a symposium. Munich, Germany, November 1, 1991.
    Am J Med; 1993 Apr; 94(4A):1S-74S. PubMed ID: 8098181
    [No Abstract]   [Full Text] [Related]  

  • 50. Detection and management of individuals and populations at risk for cardiovascular disease: Time to take a stance on cholesterol and lipoproteins. Winnipeg, Manitoba, September 14 and 15, 1987. Proceedings.
    Can J Cardiol; 1988 Jul; 4 Suppl A():1A-50A. PubMed ID: 3179798
    [No Abstract]   [Full Text] [Related]  

  • 51. [Risk factors for cardiovascular diseases in Turks in Amsterdam and in Ankara].
    Köycü B; Kara T; Camlidag O; Aydinli R; Verschuren WM; van Montfrans GA
    Ned Tijdschr Geneeskd; 1997 May; 141(18):882-8. PubMed ID: 9273453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High blood pressure research council of Australia. Cardiovascular remodelling in hypertension: the role of the renin--angiotensin system and ACE inhibition. Melbourne, Australia, 10-11 April 1992.
    Clin Exp Pharmacol Physiol Suppl; 1992; 19():1-71. PubMed ID: 1356672
    [No Abstract]   [Full Text] [Related]  

  • 54. Lives of a heart cell: tracing the origins of cardiac progenitors.
    Martin-Puig S; Wang Z; Chien KR
    Cell Stem Cell; 2008 Apr; 2(4):320-31. PubMed ID: 18397752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease.
    Nidorf SM; Eikelboom JW; Thompson PL
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):45-52. PubMed ID: 24038016
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diet and coronary heart disease: a review of the committee of diet and heart disease of the National Heart Foundation of Australia.
    Med J Aust; 1979 Sep; 2(6):294-307. PubMed ID: 392275
    [No Abstract]   [Full Text] [Related]  

  • 57. Clustering of cardiovascular risk factors in Australian adolescents: association with dietary excesses and deficiencies.
    Milligan RA; Thompson C; Vandongen R; Beilin LJ; Burke V
    J Cardiovasc Risk; 1995 Dec; 2(6):515-23. PubMed ID: 8665370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The transaminases in medical practice. Round-table discussion].
    CARBAJAL BF; BERCONSKY I
    Dia Med; 1961 May; 33():877-89. PubMed ID: 13690693
    [No Abstract]   [Full Text] [Related]  

  • 59. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.
    Holewijn S; den Heijer M; Swinkels DW; Stalenhoef AF; de Graaf J
    J Intern Med; 2010 Dec; 268(6):567-77. PubMed ID: 21091808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Folkow Symposium. Circulatory regulation--physiology and pathophysiology. Proceedings of a conference. In connection with the retirement of Processor Björn Folkow. Fiskebäckskil, Sweden, June 1987.
    Acta Physiol Scand Suppl; 1988; 571():1-207. PubMed ID: 3071080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.